期刊文献+

HER-2/neu和PIM-1在雄激素非依赖性前列腺癌中的表达及意义 被引量:1

Expression and significance of HER-2/neu and PIM-1 in androgen independent prostate cancer
下载PDF
导出
摘要 目的探讨HER-2/neu和PIM-1在雄激素非依赖性前列腺癌(AIPC)中的表达及意义。方法选取江西省人民医院2012年6月—2016年6月收治的52例前列腺肿瘤患者的病理组织,根据疾病的不同分为良性前列腺增生组18例、雄激素依赖组20例、AIPC组14例。采用免疫组织化学检测比较3组患者HER-2/neu和PIM-1基因表达及血清总前列腺特异抗原(t PSA)、游离前列腺特异抗原(f PSA),并计算F/T,并对AIPC组患者Gleason分级和临床病理分期与HER-2/neu、PIM-1基因表达的相关性进行分析。结果 AIPC组患者HER-2/neu阳性率高于良性前列腺增生组、雄激素依赖组(P<0.05);雄激素依赖组患者HER-2/neu阳性率高于良性前列腺增生组(P<0.05)。AIPC组患者PIM-1阳性率高于良性前列腺增生组、雄激素依赖组(P<0.05);良性前列腺增生组和雄激素依赖组患者PIM-1阳性率比较,差异无统计学意义(P>0.05)。经Spearman相关性分析结果显示,AIPC组患者Gleason分级与Her-2/neu阳性、PIM-1阳性无相关性(r=0.233,0.465,P>0.05)。临床病理分期与Her-2/neu阳性、PIM-1阳性呈正相关(r=0.683,0.793,P<0.05)。雄激素依赖组和AIPC组患者t PSA、f PSA高于良性前列腺增生组,F/T低于良性前列腺增生组(P<0.05);AIPC组患者F/T低于雄激素依赖组(P<0.05),但雄激素依赖组和AIPC组患者血清f PSA比较,差异无统计学意义(P>0.05)。结论原癌基因HER-2/neu、PIM-1在AIPC组织中呈高表达,并与前列腺癌细胞病理分期密切相关。 Objective To study the expression and significance of HER-2/neu and PIM-1 in androgen independent prostate cancer( AIPC). Methods A total of 52 cases of prostate neoplasms patients were selected from June 2012 to June2016 in Jiangxi Province People's Hospital,which were divided into benign prostatic hyperplasia group( n = 18),androgen dependent prostate cancer group( n = 20) and AIPC group( n = 14) according to different diseases. The expression of HER-2/neu and PIM-1 were detected by immunohistochemistry, t PSA, f PSA and F/T were detected and compared among three groups. The correlation between Gleason classification and clinical pathologic stage of AIPC group and the expression of HER-2/neu and PIM-1 were analysed. Results AIPC group of the positive rate of HER-2/neu was higher than benign prostatic hyperplasia group and androgen dependent prostate cancer group( P〈0. 05); the androgen dependent prostate cancer group of the positive rate of HER-2/neu was higher than benign prostatic hyperplasia group( P〈0. 05). AIPC group of the positive rate of PIM-1 was higher than benign prostatic hyperplasia group and androgen dependent prostate cancer group( P〈0. 05);no statistically significant difference of the positive rate of PIM-1 was found between the benign prostatic hyperplasia group and androgen dependent prostate cancer group( P〉0. 05). Spearman correlation analysis showed that no correlation between Gleason classification and the positive of HER-2/neu,PIM-1( r = 0. 233,0. 465,P〈0. 05). There was positive correlation between clinical pathologic stage and the positive of HER-2/neu,PIM-1( r = 0. 683,0. 793,P〈0. 05). Androgen dependent prostate cancer group and AIPC group of t PSA,f PSA were higher than benign prostatic hyperplasia group,F/T was lower than benign prostatic hyperplasia group( P〈0. 05). AIPC group of F/T was lower than androgen dependent prostate cancer group( P〈0. 05),no statistically significant difference of f PSA was found between AIPC group and androgen dependent prostate cancer( P〉0. 05). Conclusion The proto oncogene HER-2/neu and PIM-1 gene have high expression in androgen dependent prostate cancer tissues,and are closely related to clincial stage of prostate cancer cells stage.
出处 《临床合理用药杂志》 2017年第21期3-5,共3页 Chinese Journal of Clinical Rational Drug Use
基金 江西省自然科学基金项目(00167931511216014)
关键词 雄激素非依赖性前列腺癌 HER-2/NEU PIM-1 Androgen independent prostate cancer HER-2/neu PIM-1
  • 相关文献

参考文献7

二级参考文献67

  • 1Yeh S, Lin HK, Kang HY, et al. Proc. Natl. Acad. Sci USA 1999; 96:5458-5463.
  • 2Peiper M, Goedegebuure PS, Linehan DC, et al. Eur J Immunol 1997; 27:1115-1123.
  • 3Kono K, Rongcun Y, Charo J, et al. Int J Cancer 1998;78:202-208.
  • 4Disis ML, Gralow JR, Bernhard H, et al. J Immunol 1996; 156:3151-3158.
  • 5Esserman LJ, Lopez T, Montes R, et al. Cancer Immunol Immunother 1999; 47:337-342.
  • 6Amici A, Venanzi FM and Concetti A. Cancer Immunol Immunother 1998; 47:183-190.
  • 7Chen Y, Hu D, Eling DJ, et al. Cancer Res 1998; 58:1965-1971.
  • 8Wei WZ, Shi WE Galy A, et al. Int J Cancer 1999; 81:748-754.
  • 9Concetti A, Amici A, Petrelli C, et al. Cancer Immunol Immunother 1996; 43:307-315.
  • 10Chen S, Tsai F, Wu E et al. Clinical Cancer Research 2000; 6:4381-4388.

共引文献8

同被引文献10

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部